The driving force in hospital formularies: Economics versus efficacy

American Journal of Surgery

Volumn 186, Issue 5 SUPPL. 1, 2003, Pages 55-60

  Franklin, Glen A ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; ANTIBIOTIC AGENT; AZTREONAM; CEFAZOLIN; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DROTRECOGIN; FLUCONAZOLE; GENTAMICIN; IMMUNOGLOBULIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TELITHROMYCIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BLOOD; COLITIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; ECONOMIC ASPECT; HOSPITAL; HOSPITAL COST; HOSPITALIZATION; HUMAN; INFECTION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0348109439     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2003.10.009     Document Type: Conference Paper

References (31)

1. Shah N.D., Hoffman J.M., Vermeulen L.C., et al. Projecting future drug expenditures - 2003. Am J Health Syst Pharm. 60:2003;137-149.
2. Centers for Medicare and Medicaid Services. Health accounts. Available at: www.cms.hhs.gov/statistics/nhe/. Accessed June 8, 2003.
3. Weber R.J., Kane S.L., Oriolo V.A., et al. Impact of intensive care unit (ICU) drug use on hospital costs a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy . Crit Care Med. 1:(suppl 1):2003;S17-S24.
4. Heffler S, Smith S, Keehan S, et al. Health spending projections for 2002-2012. Health Affairs. Health tracking: trends. Available at: www.healthaffairs.org/WebExclusives/Heffler_Web_Excl_020703.htm. Accessed June 8, 2003.
5. Polk H.C. Pharmacoeconomics for surgeons. Am J Surg. 183:2002;1.
6. Google Web site. Available at: www.google.com. Accessed June 8, 2003.
7. PUBMED. Available at: www.ncbi.nlm.nih.gov/entrez/. Accessed June 8, 2003.
8. Townsend R.J. Postmarketing drug research and development. Drug Intell Clin Pharm. 21:1987;134-136.
9. Paladino J.A. Pharmacoeconomics of antimicrobial therapy. Am J Health Syst Pharm. 56:(suppl 3):1999;S25-S28.
10. Marschner J.P., Thurmann P., Harder S., Rietbrock N. J Clin Pharm Ther. 32:1994;447-451.
11. Shapiro M., Townsend T.R., Rosner B., Kass E.H. Use of antimicrobial drugs in general hospitals. N Engl J Med. 301:1979;351-355.
12. Gardner F.T., Jones C.E., Polk H.C. Further definition in antibiotic use and abuse in the surgical setting. Arch Surg. 114:1979;883-886.
13. Crossley K., Gardner L.C. Antimicrobial prophylaxis in surgical patients. JAMA. 245:1981;722-726.
14. Namias N., Harvill S., Ball S., et al. Cost and morbidity associated with antibiotic prophylaxis in the ICU. J Am Coll Surg. 188:1999;225-230.
15. Hoth J.J., Franklin G.A., Stassen N.A., et al. Prophylactic antibiotics adversely affect nosocomial pneumonia in trauma patients. J Trauma. 55:2003;249-254.
16. Alleyne C.H., Hassan M., Zabramski J.M. The efficacy and cost of prophylactic and periprocedural antibiotics in patients with external ventricular drains. Neurosurgery. 47:2000;1124-1127.
17. Simons J. King of the pill. Fortune. 7:2003;147.
18. Smith D. Pharmacoeconomics and outcomes research: some comments. Presentation at the University of Michigan ISPOR student chapter meeting; September 26, 2002; Ann Arbor, Michigan. Available at: http://www.ispor.org/ chapters/9%2026%20Slides.ppt. Accessed June 8, 2003.
19. Pear R. Drug companies increase spending to lobby Congress and governments. The New York Times June 1, 2003:A33.
20. Gouvela W.A. The rising cost of pharmaceuticals understanding and managing the escalating cost of pharmaceuticals in health care institutions . Am J Hosp Pharm. 50:(suppl 4):1993;S2-S3.
21. Rothman D.J. The rising cost of pharmaceuticals an ethicist's perspective . Am J Hosp Pharm. 50:(suppl 4):1993;S10-S12.
22. Xigris [package insert]. Indianapolis, IN: Eli Lilly and Co, 2003. Available at: http://pi.lilly.com/us/xigris.pdf. Accessed June 8, 2003.
23. Franklin G.A., Moore K.B., Snyder J.W., et al. Emergence of resistant microbes in critical care units is transient, despite an unrestricted formulary and multiple antibiotic trials. Surg Infect. 3:2002;135-144.
24. Hadjiminas D., Cheadle W.G., Spain D.A., et al. Antibiotic overkill of trauma victims? Am J Surg. 168:1994;288-290.
25. Cooke J., Kubin M., Morris T., et al. Intravenous and oral antibiotics in respiratory tract infection an international observational study of hospital practice . Pharm World Sci. 24:2002;247-255.
26. Palindino J.A., Gudgel L.D., Forrest A., Niederman M.S. Cost-effectiveness of IV-to-oral switch therapy azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia . Chest. 122:2002;1271-1279.
27. Castro-Guardiola A., Viejo-Rodriguez A.L., Soler-Simon S., et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia a randomized controlled trial . Am J Med. 111:2001;367-374.
28. Lelekis M., Gould I.M. Sequential antibiotic therapy for cost containment in the hospital setting why not? J Hosp Infect. 48:2001;249-257.
29. Wunderink R.G. Pharmacoeconomics of pneumonia. Am J Surg. 179:(suppl 2A):2000;S51-S57.
30. Croce M.A., Fabian T.C., Stewart R.M., et al. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma. 35:1993;303-311.
31. Fernandez-Guerrero M., Gudiol F., Rodriguez-Torres A., et al. Nosocomial pneumonia comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations . Infection. 19:(suppl 6):1991;S320-S325.